| Wang Penghui,Gong Shuai,Ding Shouliang,et al.Application of the ArcherQA three-dimensional dose verification system in intensity-modulated radiotherapy plans for nasopharyngeal carcinoma[J].Chinese Journal of Radiological Medicine and Protection,2022,42(8):598-604 |
| Application of the ArcherQA three-dimensional dose verification system in intensity-modulated radiotherapy plans for nasopharyngeal carcinoma |
| Received:April 09, 2022 |
| DOI：10.3760/cma.j.cn112271-20220409-00150 |
| KeyWords:ArcherQA Three-dimensional dosimetric verification Nasopharyngeal carcinoma Intensity-modulated radiotherapy |
| FundProject:国家自然科学基金（11805292）；广东省自然科学基金（2018A0303100020）；广东省基础与应用基础粤穗联合青年基金（2021A1515110642）；中华国际医学交流基金会肿瘤精准放疗星火计划（2019-N-11-34） |
| Author Name | Affiliation | E-mail | | Wang Penghui | Radiotherapy Center, Qingdao Municipal Hospital Affiliated to Qingdao University Medical College, Qingdao 266011, China | | | Gong Shuai | Radiotherapy Center, Qingdao Municipal Hospital Affiliated to Qingdao University Medical College, Qingdao 266011, China | | | Ding Shouliang | State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Radiation Oncology of Sun Yat-sen University Cancer Center, Guangzhou 510060, China | | | Yang Lu | Radiotherapy Center, Affiliated Tumor Hospital of Guangzhou Medical University, Guangzhou 510095, China | | | Wang Meng | Radiotherapy Center, Qingdao Municipal Hospital Affiliated to Qingdao University Medical College, Qingdao 266011, China | | | Pei Xi | Nuclear Medical Physics Institute, University of Science and Technology of China, Hefei 210027, China | | | Huang Xiaoyan | State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Radiation Oncology of Sun Yat-sen University Cancer Center, Guangzhou 510060, China | | | Liu Hongdong | State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Radiation Oncology of Sun Yat-sen University Cancer Center, Guangzhou 510060, China | liuhd@sysucc.org.cn |
|
| Hits: 3674 |
| Download times: 1204 |
| Abstract:: |
| Objective To investigate the feasibility of applying the ArcherQA three-dimensional (3D) dosimetric verification system in intensity-modulated radiotherapy (IMRT) plans for nasopharyngeal carcinoma (NPC).Methods A retrospective analysis was conducted for 105 NPC patients' IMRT plans developed using the Eclipse treatment planning system (TPS). Dose verification was conducted using the ArcherQA system and through portal dosimetry (PD). Moreover, this study compared γ passing rates (criteria:3 mm/3%, TH=10%) between ArcherQA and PD and the doses delivered to the target volume (Dmean, D90%) and organs at risk (OARs) (Dmean) between ArcherQA and TPS, and analyzed the 3D γ passing rates of each organ at risk calculated by ArcherQA.Results The average 3D γ passing rate calculated by ArcherQA was (99.04±1.01)%, and the average 2D γ passing rate measured by PD was (99.49±0.78)%, with statistically significant differences (t=-3.35, P< 0.05). The dosimetric differences to the target volume between ArcherQA and TPS were as follows:the average difference in Dmean to the gross tumor volume (GTV) was (0.57±0.48)%, and the average difference in D90% was (0.65±0.56)%. For the target volume, the average γ passing rate was (97.67±3.43)% for GTV, (97.80±4.35)% for GTVnd-L, (97.82±4.07)% for GTVnd-R, (97.88±2.44)% for CTV1, and (96.64±4.32)% for CTV2. The mean dose difference of each target volume was CTV1 (0.57±0.46)%, GTVnd-L (0.85±0.55)%, GTVnd-R (0.73±0.55)%, and CTV2 (0.88±0.52)%. For OARs, the mean γ passing rate was (99.93±0.22)% for the brainstem, (99.17±2.82)% for the optic chiasm, (100±0)% for the lens, (99.56±1.05)% for the spinal cord, (99.00±2.06)% for the thyroid, and (87.86±10.42)% for the trachea. Statistically significant differences in the average doses to OARs were observed (t=-14.62 to 4.82, P<0.05), except for those to the left optic nerve, the right hippocampus, and the right parotid gland.Conclusions Based on the high-performance GPU platform and the Monte Carlo dose algorithm, ArcherQA can provide accurate 3D dose distribution and 3D γ passing rates inside patients according to CT images and provide the dose volume histogram (DVH) of various regions of interest (ROIs). Therefore, the ArcherQA three-dimensional dose verification system can be applied to IMRT plans for NPC. Moreover, it is inducive to improve the treatment efficiency since it does not occupy the accelerator operation time. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
